Cytek Biosciences, a leading flow cytometry company, has invested US$3 million in its Singapore facility as part of its strategy to expand manufacturing and regional operations. The facility, launched in the first quarter of 2025, is the company’s fourth global manufacturing site and underscores Singapore’s appeal due to its robust biomedical ecosystem, strong regulatory framework, skilled talent pool, advanced infrastructure, and strategic location within the Asia-Pacific (Apac) region.
The 8,500-square-foot facility in JTC Corporation’s One North Coast in Woodlands serves as a strategic hub for Cytek, enhancing its manufacturing capacity, supply chain resilience, and training capabilities while offering regional customers hands-on access to instruments and advanced technical expertise.
Cytek creates advanced instruments that enable scientists to study cells in greater detail, better understand diseases, and develop advanced therapies. The Singapore facility supports growing demand for cell analysis across fields such as immunology, infectious diseases, and cancer diagnosis. The site also features a dedicated service and training centre, providing regional customers with hands-on access to Cytek’s products and expertise.
Dr. Jiang Wenbin, CEO of Cytek, said that the investment is part of a broader strategy to deepen the company’s engagement across Apac. “This investment is not just about Singapore, but the whole Asia-Pacific region,” he emphasized.
The expansion has already shown results, enhancing production scalability, improving supply chain agility, and reducing delivery times in key markets. For FY2025, Cytek reported a 1% year-on-year revenue increase to US$201.5 million, driven by growth in Apac and the United States. North America accounted for 48% of total revenue, with Europe contributing nearly 30%, and APAC and Latin America making up the remainder.
The Singapore facility currently employs 25 staff across manufacturing, engineering, supply chain, and scientific support functions. Cytek is also collaborating with leading Singapore institutions, including the National University of Singapore, the Agency for Science, Technology and Research, and Singapore General Hospital, to foster innovation and talent development.
Melik Ulusu, senior vice-president of global operations and integrated supply chain at Cytek, highlighted the company’s laser-based flow cytometry solutions, which are instrumental in advancing scientific discovery and improving patient care, particularly in areas like cancer and HIV treatment. The company’s products are widely used by pharmaceutical companies, clinical research laboratories, and academic institutions, with over 3,000 instruments deployed globally across more than 70 countries.
To commemorate the facility’s first anniversary, Cytek hosted a milestone event attended by distinguished guests, including Member of Parliament Mariam Jaafar (Sembawang GRC) and Marcus Dass, senior vice-president and head of global enterprises at the Singapore Economic Development Board. Dass noted that the investment bolsters advanced manufacturing capabilities while contributing to life sciences research through Cytek’s cell analysis technologies.
The expansion aligns with rising global demand for cell analysis solutions, driven by the increasing use of cellular analysis in fields such as immunology, immuno-oncology, infectious diseases, cancer diagnosis, and drug development. This demand positions Cytek to play a pivotal role in supporting cutting-edge research and healthcare advancements in the region and beyond.
Headquartered in California and listed on Nasdaq, Cytek also operates facilities in China, further solidifying its global presence. The Singapore expansion reflects the company’s commitment to meeting the growing needs of the life sciences industry while strengthening its footprint in APAC.
